Aclidinium

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Aclidinium
   1. Pharmacist Assessment Report
   2. Aclidinium: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Aclidinium: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Aclidinium, so there is currently no new predicted indication. The uses recorded for this drug are listed below; none are recorded at present.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
10124W	Bretaris Genuair	Powder for oral inhalation in breath act	Valid

Safety Considerations

Drug Interactions: 100 potential interactions were identified. The 20 listed in the data compiled for this report are all rated Moderate, and most are other anticholinergic or antimuscarinic agents, where additive effects are expected. Examples:

• Atropine
• Clidinium
• Dicyclomine
• Glycopyrronium
• Hyoscyamine
• Scopolamine
• Trospium
• Amitriptyline
• Promethazine
• Chlorpheniramine

Others include eluxadoline, prucalopride, acetylcholine and inhaled human insulin.

Ocular concern: as a muscarinic antagonist, aclidinium may raise intraocular pressure or precipitate angle closure, which is directly relevant to the predicted glaucoma indication.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---